<DOC>
	<DOCNO>NCT02960555</DOCNO>
	<brief_summary>The goal clinical research study learn isatuximab help control smolder multiple myeloma ( SMM ) . The safety drug also study .</brief_summary>
	<brief_title>Trial Isatuximab ( SAR650984 ) Patients With High Risk Smoldering Multiple Myeloma</brief_title>
	<detailed_description>Study Drug Administration : Participant receive isatuximab vein 1 hour Days 1 , 8 , 15 , 22 28-day cycle first month . During Months 2-6 , participant receive isatuximab Days 1 15 . After Month 6 , participant receive isatuximab Day 1 . Participant give standard drug help decrease risk side effect . Participant may ask study staff information drug give risk . Study Visits : On Day 1 cycle : - Participant physical exam . - Blood ( 2-3 tablespoon ) draw routine test , check anti-drug antibody , check status disease . - Blood ( 3 teaspoon ) draw genetic testing . - Starting Cycle 2 , urine collect 24 hour routine test check status disease . - If participant able child , blood ( 1 teaspoon ) collect pregnancy test . On Day 2 Cycle 1 : - Blood ( 1-2 tablespoon ) draw genetic testing . - Urine collect routine test check status disease . On Days 8 , 15 22 Cycle 1 : - Blood ( 1-2 tablespoon ) draw routine test check status participant 's disease . - On Day 15 , urine collect routine test check status disease . - On Day 15 , blood ( 1 teaspoon ) collect check anti-drug antibody . - If participant able child , blood ( 1 teaspoon ) collect pregnancy test . On Day 28 Cycles 6 , 18 , 30 : - Blood ( 3 teaspoon ) draw genetic testing . - Participant skeletal survey check status disease . - Participant bone marrow biopsy/aspiration check status disease , genetic testing , biomarker testing ( include genetic biomarkers ) . - If doctor think need , participant MRI and/or FDG-PET/CT scan . If participant become pregnant , participant regular menstrual cycle , blood ( 1 teaspoon ) urine collect pregnancy test 1 time week Cycle 1 1 time every cycle . If participant irregular menstrual cycle , participant test 1 time week Cycle 1 2 time every cycle . If disease appear get bad , time doctor think need , participant may test procedure repeat check status disease . Length Study : Participant may continue take isatuximab 30 month . Participant longer able take study drug disease get bad , intolerable side effect occur , participant unable follow study direction . Participation study long-term follow-up complete . End Treatment : Two week last dose isatuximab : - If participant able child , blood ( 1 teaspoon ) collect pregnancy test . - Blood ( 1 teaspoon ) collect check anti-drug antibody . Follow-Up : Within 28 day participant 's last dose study drug : - Participant physical exam . - Blood ( 2-3 tablespoon ) draw routine test , check anti-drug antibody , check status disease . - Blood ( 3 teaspoon ) draw genetic testing . - Urine collect 24 hour routine test check status disease . - If participant become pregnant , blood ( 1 teaspoon ) urine collect pregnancy test . If participant irregular menstrual cycle , participant also test within 14 day participant 's last dose . Long-Term Follow-Up : After participant 's last dose study drug , participant call member study staff ask participant , participant side effect , participant start new anti-cancer treatment . This call last 15-20 minute . Participant receive call least every 6-12 month end study . If participant serious side effect , participant may call often check participant . This follow-up stop disease get bad . If participant routine clinic visit participant 's doctor , question ask participant 's clinic visit participant may receive phone call . This investigational study . Isatuximab FDA approve commercially available . It currently use research purpose . The study doctor explain study drug design work . Up 61 participant enrol multicenter study . Up 42 take part MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>1 . Patients must histologically confirm SMM base follow criterion . Both criterion must meet : ( ) Serum monoclonal protein ( IgG IgA ) &gt; /= 3 g/dL urinary monoclonal protein &gt; /= 500 mg per 24 hour and/or clonal bone marrow plasma cell 1060 % ( b ) Absence myeloma define event amyloidosis . 2 . Additionally , patient must meet criterion high risk progression multiple myeloma PETHEMA CRITERIA ( patient must least 2 risk factor present ) 1 . &gt; /=95 % abnormal plasma cells/total plasma cell bone marrow compartment ( This measure percentage total abnormal versus normal plasma cell bone marrow compartment use standard flow cytometry bone marrow aspirate . Having &gt; /=95 % abnormal plasma cells/total plasma cell constitute risk factor progression multiple myeloma PETHEMA criterion ) 2 . Immunoparesis ( This term refer patient low uninvolved immunoglobulin peripheral blood , example patient IgA smolder multiple myeloma , either low IgM and/or low IgG qualify risk factor progression multiple myeloma ) *2 2 risk factor : high risk progression rate 72 % 5 year 3 . Creatinine clearance ( CrCl ) &gt; /= 40 ml/min . CrCl calculate use Modification Diet Renal Disease ( MDRD ) equation . 4 . Age &gt; /= 18 year . Because dose adverse event data currently available use Isatuximab patient &lt; 18 year age , child exclude study . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 6 . Absolute neutrophil count ( ANC ) &gt; /=1.0 x 10^9 /L , hemoglobin &gt; /= 11 g/dL platelet count &gt; /=90 x 10^9/L . Platelet blood transfusion allow protocol . Growth factor , include granulocyte colony stimulate factor erythropoietin allow . 7 . Adequate hepatic function , bilirubin &lt; 1.5 x ULN , AST ALT &lt; 3.0 x ULN . 8 . Females childbearing potential male subject female partner childbearing potential must agree avoid pregnancy use adequate method contraception ( 2 barrier method 1 barrier method spermicide intrauterine device 2 week prior screen , 12 week last dose trial medication . Adequate method contraception provide example . Other acceptable effective method birth control also permit ( eg , abstinence ) . 9 . Men must agree donate sperm study least 3 month last dose study drug ( ) . Women child bear potential must negative serum pregnancy test result within 7 day prior first administration isatuximab end treatment visit . A negative urine pregnancy test require prior subsequent isatuximab dose administration . 10 . Subjects must able give informed consent 1 . Evidence myeloma define event biomarkers malignancy due underlie plasma cell proliferative disorder meeting least ONE following : 1 . Hypercalcemia : serum calcium &gt; 0.25 mmol/L ( &gt; 1 mg/dL ) high upper limit normal &gt; 2.75 mmol/L ( &gt; 11 mg/dL ) 2 . Renal Insufficiency : creatinine clearance &lt; 50 ml/min serum creatinine &gt; 2 mg/dL 3 . Anemia : hemoglobin value &lt; 10 g/dL 2 g/dL &lt; normal reference 4 . Bone lesion : one osteolytic lesion skeletal radiography , computerize tomography ( CT ) 2deoxy2 [ F18 ] fluoroDglucose positron emission tomography CT ( PETCT ) 5 . Clonal bone marrow plasma cell percentage &gt; /= 60 % 6.Involved : uninvolved serum free light chain ratio &gt; /=100 measure Freelite assay ( The Binding Site Group , Birmingham , UK ) 7 . &gt; 1 focal lesion MRI study ( focal lesion must 5 mm size ) 2 . Prior concurrent systemic treatment SMM . b ) Bisphosphonates permitted , include pamidronate , zoledronic acid , alendronate , ibandronate , risedronate . c ) Treatment corticosteroid permit , unless patient stable chronic dose inhaled steroid treat respiratory diseases stable chronic steroid replacement therapy endocrinology disorder . ) Radiotherapy permit . e ) Prior treatment smolder multiple myeloma chemotherapy agent approve treatment multiple myeloma CD38 drug permit . 3 . Plasma cell leukemia 4 . Pregnant lactating female . Because potential risk adverse event nurse infant secondary treatment mother isatuximab , breastfeed discontinue mother treated isatuximab . These potential risk may also apply agent use study . 5 . Active hepatitis B C infection . 6 . Known HIV infection 7 . Intolerance infuse protein product , sucrose , histidine polysorbate 80 . 8 . Concurrent treatment anticancer therapy permit . 9 . Has significant cardiovascular disease NYHA Class III IV symptom , hypertrophic cardiomyopathy , restrictive cardiomyopathy , myocardial infarction within 3 month prior enrollment , unstable angina , unstable arrhythmia determine history physical examination . 10 . Uncontrolled intercurrent illness include limited active infection psychiatric illness/social situation would compromise compliance study requirement 11 . Contraindication concomitant medication , include premedications hydration give prior therapy 12 . Major surgery within 1 month prior enrollment 13 . Patients preexist pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Smoldering Multiple Myeloma</keyword>
	<keyword>SMM</keyword>
	<keyword>Intermediate high risk</keyword>
	<keyword>SAR650984</keyword>
	<keyword>Diphenhydramine</keyword>
	<keyword>Benadryl</keyword>
	<keyword>Ranitidine</keyword>
	<keyword>Ranitidine Hydrochloride</keyword>
	<keyword>Zantac</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Depo-Medrol</keyword>
	<keyword>Medrol</keyword>
	<keyword>Solu-Medrol</keyword>
</DOC>